RBR-4yr9mt
Not yet recruiting
Phase 4
Evaluation of the effects of oxytocin in patients with schizophrenia
Faculdade de Medicina de Ribeirão Preto0 sitesSeptember 22, 2020
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Faculdade de Medicina de Ribeirão Preto
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General: Men aged 18 to 50 years, literate, signing the Informed Consent Form.
- •For the clinical group, the participants must have a diagnosis of Refractory Schizophrenia, with a disease duration between 10 and 15 years, be on an outpatient treatment, using Clozapine exclusively and without psychiatric comorbidities.
- •For the control group, participants must have no current or previous psychiatric disorder and use any psychotropic drugs. For Phase 3 of the study, participants in the control group must be overweight (BMI greater than 25kg / m2\).
Exclusion Criteria
- •For clinical and control group: presence of clinical diseases of great impact on the functioning of the organism, such as degenerative, neurological diseases, cancers, hematological, pulmonary, renal, liver, cardiovascular diseases and / or use of psychoactive substances.
- •For Phase 3: participants using oral antidiabetics, lipid\-lowering drugs, sibutramine, amphetamines, orlistat or other medications for the treatment of excess weight will also be excluded. Participants with schizophrenia who experience any change in their medication or therapeutic prescriptions during the period of participation in the study will be automatically excluded
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-PersönlichkeitsstörungICD-10 F60.3 Emotionally unstable personality disorderTwo types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline type, characterized in addition by disturbances in self-image, aims, and internal preferences, by chronic feelings of emptiness, by intense and unstable interpersonal relationships, self-destructive behaviour, including suicide gestures and attempts.Clinical control group: major depression (ICD-10 F33)MedDRA version: 17.1Level: PTClassification code 10006034Term: Borderline personality disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 17.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-020956-69-DEniversitätsklinikum Freiburg250
Completed
Not Applicable
A research of efficacy and safety of oxytocin treatment in children and adolescents with reactive attachment disorder using functional magnetic resonance imaging (fMRI).Reactive Attachment DisorderJPRN-UMIN000013215niversity of Fukui, Research Center for Child Mental Development, Division of Psychosocial Support for Nurturing55
Completed
Not Applicable
A research of efficacy and safety of oxytocin administration to detect others altruism in children and adolescents with reactive attachment disorder.JPRN-UMIN000016389niversity of Fukui, Research Center for Child Mental Development, Division of Psychosocial Support for Nurturing85
Completed
Phase 2
Evaluation of Oxytocin,s effect in comparison with placebo on craving; withdrawal and stress response due to heroin.Condition 1: Withdrawal syndrome. Condition 2: Craving.Mental and behavioural disorders due to use of opioidsIRCT2015103024792N1Vice chancellor for research Kashan University of Medical Sciences50
Completed
Phase 2
abor induction for premature rupture of membranespremature rupture of membranes at term.Preterm spontaneous labour with preterm deliveryIRCT2016042627615N1Vice Chancellor for Research, Mashhad University of Medical Sciences86